Latest news with #NutexHealth
Associated Press
17 hours ago
- Business
- Associated Press
NUTEX HEALTH INC. ADDED TO RUSSELL 3000® INDEX AND RUSSELL MICROCAP® INDEX
HOUSTON, June 24, 2025 /PRNewswire/ -- Nutex Health Inc. ('Nutex Health' or the 'Company') (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced it has been added as a member of the broad-market Russell 3000® Index and the Russell Microcap® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest U.S. stocks as of April 30, ranking them by total market capitalization. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. 'Inclusion in the Russell Indexes is great validation of the Nutex Health business model and will help increase our visibility with long term institutional investors,' stated Jon Bates, Chief Financial Officer of Nutex Health. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the 'Russell Reconstitution' section on the FTSE Russell website. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. About FTSE Russell, an LSEG Business FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit FTSE Russell. Forward-Looking Statements Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, under the heading 'Risk Factors' in Part II, Item IA thereof, and the risk factors and other cautionary statements contained in our other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. View original content: SOURCE Nutex Health, Inc.
Yahoo
13-05-2025
- Business
- Yahoo
NUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
TOTAL REVENUE OF $211.8 MILLION VERSUS $67.5 MILLION IN Q1 2024, AN INCREASE OF 213.8% NET INCOME ATTRIBUTABLE TO NUTEX HEALTH INC. OF $14.6 MILLION VERSUS NET LOSS OF $0.4 MILLION IN Q1 2024 DILUTED EPS OF $2.56 PER SHARE VERSUS $(0.08) PER SHARE IN Q1 2024 EBITDA OF $43.1 MILLION VERSUS $7.1 MILLION IN EBITDA IN Q1 2024, AN INCREASE OF 507.0% ADJUSTED EBITDA OF $72.8 MILLION VERSUS $(0.4) MILLION IN Q1 2024 NET CASH FROM OPERATING ACTIVITIES OF $51.0 MILLION COMPANY BELIEVES ITS ARBITRATION EFFORTS THROUGH THE INDEPENDENT DISPUTE RESOLUTION (IDR) PROCESS HAVE RESULTED IN MORE FAIR AND REASONABLE PAYMENTS HOUSTON, May 13, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today announced first quarter 2025 financial results for the three months ended March 31, 2025. Financial highlights for the three months ended March 31, 2025: Total revenue increased $144.3 million to $211.8 million for the three months ended March 31, 2025 as compared to total revenue of $67.5 million for the same period in 2024, an increase of 213.8%. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2022, increased by 186.5% in 2025 compared to 2024. The arbitration process resulted in approximately $105.0 million more in revenue in the three months ended March 31, 2025 than the same period in 2024, which amounted to 73.1% of the $144.3 million revenue increase. Of the $105.0 million in arbitration revenue, $60.0 million, $26.0 million and $19.0 million related to dates of services for the first quarter 2025, fourth quarter 2024 and pre-fourth quarter 2024, respectively. Total stock-based compensation expense for the three months ended March 31, 2025 was $36.1 million compared to less than $0.1 million for the same period in 2024. Approximately 99% of total stock-based compensation expense of $36.1 million is due to the one-time obligations for under-construction and ramping hospitals. Operating income for the three months ended March 31, 2025 was $72.2 million compared to $1.5 million for the same period in 2024, representing a $70.7 million improvement year over year. Net income attributable to Nutex Health for the three months ended March 31, 2025 of $14.6 million as compared to net loss attributable to Nutex Health of $0.4 million for the same period in 2024. The $14.6 million in net income includes non-cash stock-based compensation expense of $36.1 million, while the $0.4 million net loss includes no non-cash stock-based compensation expense. EBITDA attributable to Nutex Health of $43.1 million, as compared to EBITDA attributable to Nutex Health of $7.1 million for the three months ended March 31, 2024, an increase of 507.0%. Adjusted EBITDA attributable to Nutex Health of $72.8 million, as compared to Adjusted EBITDA attributable to Nutex Health of $(0.4) million for the three months ended March 31, 2024. Total visits at the Hospital Division were 48,269 for the three months ended March 31, 2025, as compared to 40,068 for the same period in 2024, an increase of 8,201 or 20.5%. Visits at mature hospitals increased by 5.3% in the three months ended March 31, 2025 as compared to the same period in 2024. Net cash from operating activities of $51.0 million for the three months ended March 31, 2025. As of March 31, 2025, the Company had total assets of $761.9 million, including cash and cash equivalents of $87.7 million, and long-term debt of $21.7 million. Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release. "We are excited to provide yet another solid quarter with $14.6 million in net income, a record high gross profit of 56%, a record high $51.0 million in net cash from operating activities and a record high cash balance of $87.7 million, highlighting the company's continued financial strength as we execute on our growth plan for 2025," stated Jon Bates, Chief Financial Officer of Nutex Health. "In 2024, Nutex Health achieved significant operational improvements across all key metrics. Total hospital division visits increased by 20.5%, driven by higher ER acuity and an enhanced service mix, with greater focus on observation patients and inpatients. In 2025, we will continue optimizing operations and maintaining a lean cost structure to support sustained growth," said Josh DeTillio, Chief Operating Officer of Nutex Health. "The great momentum that we started in 2024 is continuing into the first quarter of 2025. We are now seeing more consistent financial results stemming from a combination of volume growth and operational efficiency, with more fair and reasonable payments from the arbitration process. We still have a lot of work ahead of us, but the positive trend is very encouraging. We would like to thank our team of physicians and team members nationwide for working in alignment to get us to where we are this quarter," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health. For more details on the Company's first quarter 2025 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at NUTEX HEALTH INC. CONSOLIDATED BALANCE SHEETS (Unaudited)(In thousands, except share and per share amounts)March 31, 2025December 31, 2024 Assets Current assets: Cash and cash equivalents$ 87,670$ 43,581 Accounts receivable 295,082 232,449 Accounts receivable - related parties 4,258 3,602 Inventories 3,118 2,850 Prepaid expenses and other current assets 11,389 9,998 Total current assets 401,517 292,480 Property and equipment, net 76,431 77,933 Operating right-of-use assets 27,466 27,872 Finance right-of-use assets 216,193 218,889 Intangible assets, net 15,205 15,530 Goodwill, net 13,919 13,919 Deferred tax assets 10,487 7,987 Other assets 698 711 Total assets$ 761,916$ 655,321Liabilities and Equity Current liabilities: Accounts payable$ 19,836$ 9,614 Accounts payable - related parties 5,679 4,345 Lines of credit 7,126 3,554 Current portion of long-term debt 13,635 14,395 Operating lease liabilities, current portion 2,103 2,080 Finance lease liabilities, current portion 8,027 7,705 Accrued arbitration expenses 51,803 47,742 Accrued income tax expense 43,718 25,989 Accrued expenses and other current liabilities 24,639 25,442 Total current liabilities 176,566 140,866 Long-term debt, net 21,733 22,466 Operating lease liabilities, net 30,350 30,617 Finance lease liabilities, net 258,387 259,479 Total liabilities 487,036 453,428Commitments and contingencies (Note 9)Equity: Common stock, $0.001 par value; 950,000,000 shares authorized; 5,528,448 and 5,511,452 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 6 6 Additional paid-in capital 539,361 503,233 Accumulated deficit (342,259) (356,893) Nutex Health Inc. equity 197,108 146,346 Noncontrolling interests 77,772 55,547 Total equity 274,880 201,893 Total liabilities and equity$ 761,916$ 655,321 NUTEX HEALTH INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months Ended March 31, (In thousands, except share and per share amounts)20252024 Revenue: Hospital division$ 203,947$ 60,029 Population health management division 7,842 7,424 Total revenue 211,789 67,453Operating costs and expenses: Payroll 34,860 27,003 Contract services 38,655 11,319 Medical supplies 3,801 5,322 Depreciation and amortization 5,092 4,186 Other 11,043 9,466 Total operating costs and expenses 93,451 57,296 Gross profit 118,338 10,157Corporate and other costs: Stock-based compensation 36,094 49 General and administrative expenses 10,035 8,658 Total corporate and other costs 46,129 8,707 Operating income 72,209 1,450Interest expense, net 6,120 4,444 Gain on warrant liability - (2,601) Other (income) expense 3,325 (241) Income (loss) before taxes 62,764 (152) Income tax expense 18,541 390Net income (loss) 44,223 (542) Less: net income (loss) attributable to noncontrolling interests 29,589 (178)Net income (loss) attributable to Nutex Health Inc.$ 14,634$ (364)Income (loss) per common share: Basic$ 2.65$ (0.08) Diluted$ 2.56$ (0.08) NUTEX HEALTH INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)Three Months Ended March 31, (In thousands)20252024 Cash flows from operating activities: Net income (loss)$ 44,223$ (542) Adjustments to reconcile net income (loss) to net cash from operating activities: Depreciation and amortization 5,092 4,186 Gain on warrant liability - (2,601) Stock-based compensation expense 36,094 49 Deferred tax (benefit) expense (2,500) (95) Debt accretion expense 253 365 Changes in operating assets and liabilities, net of the effects of acquisitions: Accounts receivable (62,633) (2,909) Accounts receivable - related party (656) (62) Inventories (268) 415 Prepaid expenses and other current assets (1,378) 796 Operating right-of-use assets 406 273 Accounts payable 10,222 (1,681) Accounts payable - related party 1,334 475 Operating lease liabilities (245) (376) Accrued arbitration expenses 4,061 - Accrued income tax expense 17,729 - Accrued expenses and other current liabilities (769) 4,758 Net cash from operating activities 50,965 3,051Cash flows from investing activities: Acquisitions of property and equipment (64) (733) Net cash from investing activities (64) (733)Cash flows from financing activities: Proceeds from lines of credit 3,864 - Proceeds from long-term debt 157 2,915 Repayments of lines of credit (292) (595) Repayments of long-term debt (1,810) (4,388) Repayments of finance leases (1,367) (968) Proceeds from common stock issuance, net issuance costs - 9,203 Members' distributions (7,364) (481) Net cash from financing activities (6,812) 5,686 Net change in cash, cash equivalents and restricted cash 44,089 8,004 Cash, cash equivalents and restricted cash - beginning of the period 43,581 22,002 Cash, cash equivalents and restricted cash - end of the period$ 87,670$ 30,006 Non-GAAP Financial Measures (Unaudited) EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance. We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization. We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net income to Adjusted EBITDA is included below. Beginning in the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842, which were previously included in interest expense, net and depreciation and amortization. We believe this change provides greater transparency into our operating performance. Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. Three Months Ended March 31, 20252024 Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA: (Updated) (Prior) (Updated) (Prior) Net income (loss) attributable to Nutex Health Inc.$ 14,634$ 14,634$ (364)$ (364) Depreciation and amortization 5,092 5,092 4,186 4,186 Interest expense, net 6,120 6,120 4,444 4,444 Income tax expense 18,541 18,541 390 390 Allocation to noncontrolling interests (1,297) (1,297) (1,544) (1,544) EBITDA 43,090 43,090 7,112 7,112 Gain on warrant liability - - (2,601) (2,601) Finance lease payments(1) (6,363) - (4,972) - Stock-based compensation 36,094 36,094 49 49 Adjusted EBITDA$ 72,821$ 79,184$ (412)$ 4,560(1) Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Forward-Looking Statements Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q for the three months ended March 31, 2025 under the heading "Risk Factors" in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. View original content: SOURCE Nutex Health, Inc.
Associated Press
07-05-2025
- Business
- Associated Press
Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call
HOUSTON, May 7, 2025 /PRNewswire/ -- Nutex Health Inc. ('Nutex Health' or the 'Company') (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals in 11 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of the stock market on Tuesday, May 13, 2025. The Company will discuss those results on a conference call on Wednesday, May 14, 2025, at 10:30 a.m. ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website . About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Forward-Looking Statements Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases 'will', 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' 'goal,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended year ended December 31, 2024 under the heading 'Risk Factors' in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. View original content: SOURCE Nutex Health, Inc.
Yahoo
21-04-2025
- Business
- Yahoo
Nutex Health Inc. (NUTX): Among Most Expensive Stocks Insiders Are Buying After Trump's Tariff Rollout
We recently published a list of . In this article, we are going to take a look at where Nutex Health Inc. (NASDAQ:NUTX) stands against other most expensive stocks insiders are buying after Trump's tariff rollout. Wall Street banks have sharply cut their targets for the broader market index due to growing fears about the economic fallout from new tariffs, writes the Financial Times. Since the tariff announcement on April 2, the broader market index has dropped nearly 7%. Major banks now expect lower market gains in 2025, with some analysts predicting a possible bear market directly triggered by presidential policy shifts. Amid tariff wars and market uncertainty, insider trading often draws attention. Insider stock purchases may signal executive confidence, while sales aren't necessarily negative—they could reflect personal or diversification choices. It's best to view insider trading in context with a company's financials and market conditions. Today, we're highlighting most expensive stocks that insiders have been buying in April. Using Insider Monkey's trading screener, we looked for companies with share prices of at least $30 and insider purchases between April 2 and April 21. From there, we ranked the top 12 stocks based on the highest average purchase price per share. Stocks that were recently covered were excluded from this list. Most of those can be seen on this list of the 19 mid- and large-cap stocks insiders are buying after Trump's tariff rollout. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A medical professional in scrubs providing care to a patient. Nutex Health Inc. (NASDAQ:NUTX) is a physician-led healthcare services and operations company based in Houston, Texas. It operates through three segments: Hospital, Population Health Management, and Real Estate, offering services like 24/7 emergency and inpatient care, imaging, labs, and pharmacy support. The company also manages physician groups, runs a cloud-based healthcare platform, and owns hospital properties across the U.S. On April 8, the company's CFO Christian Jon Bates purchased around $81,810 worth of Nutex Health shares at an average price of $81.81 per share. Year-to-date, the stock gained 370.18% and is now trading at $149 per share. Over the past 12 months, Nutex Health returned 2,962.55% to its investors. For the year ended December 31, 2024, Nutex Health (NASDAQ:NUTX) reported total revenue of $479.9 million, up 93.8% from 2023, driven largely by $169.7 million in arbitration-related revenue. The company achieved $130.6 million in operating income, a major turnaround from a $31.8 million loss the previous year, and posted net income of $52.2 million. Adjusted EBITDA soared to $123.7 million, up over 1,000% year-over-year, with hospital visits rising nearly 17% to 168,388. Nutex Health (NASDAQ:NUTX) is also one of the . Overall, NUTX ranks 3rd on our list of most expensive stocks insiders are buying after Trump's tariff rollout. While we acknowledge the potential of NUTX, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NUTX but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
